Hormone receptor testing mainly serves the purpose of guiding treatment choices for breast cancer patients.Patients with estrogen receptor(ER)-positive breast cancers show significant response to endocrine therapy.However,the methods to define ER status and eligibility for treatment remain controversial....
npj Breast CancerLumachi F, Brunello A, Maruzzo M, Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013 ;20(5):596–604.Lumachi F, Brunello A, Maruzzo M, Basso U, Basso SM. Treatment of estrogen receptor-positive breast cancer. Curr Med Chem. 2013; 20 (5):...
Comprehensive Cancer Center, Los Angeles, CA, discusses how fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) compares with physician’s choice of chemotherapy in estrogen receptor (ER)-positive/HER2-low breast cancer and how progression speed may influence a clinicians treatment choice between the...
Whereas breast cancer tissue samples considered ER-positive (1% to 100% of tumor nuclei are positive for ER) are associated with benefit from the use of endocrine therapy, the authors acknowledge that the suitability of the treatment is much more nebulous for low ER-positive cases, which represe...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
其中对于Luminal型HER2低表达乳腺癌的生物学特征,到底是由ER还是由HER2信号通路相关基因驱动,至今并没有本质的认识。并且HER2低表达是否影响患者预后其结果不一。总的来说,目前关于HER2低表达能否作为独立的亚型,仍然存在争议。在今年的SABCS大会上,来自...
PET/CT and breast MRI exhibit high predictive values for identifying low-burden axillary metastasis in patients with operable breast cancer with ≦ 2 positive ALNs on imaging.Introduction Sentinel lymph node biopsy (SLNB) has become the mainstay of axillary surgical staging in breast cancer patients...
Miglietta F, Griguolo G, Bottosso M et al (2022) HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer 8:66 Article CAS PubMed PubMed Central Google Scholar Prat A, Bardia A, Curigliano G et al (2022) An overvi...
Dr. Paolo Tarantino discusses the current treatment landscape of ER+/HER2- low metastatic breast cancer and unmet needs.
In HR-positive/HER2-negative primary breast cancer cohort, a statistically significant association was observed between HER2-low expression and both Luminal B-like phenotype (Luminal B-like proportion in HER2-0 vs HER2-low: 51.9% vs 64.7%, respectively, p = 0.023) and higher ER expression...